|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||131.27 - 132.39|
|52 Week Range||109.32 - 137.08|
|PE Ratio (TTM)||22.23|
|Dividend & Yield||3.36 (2.48%)|
|1y Target Est||N/A|
The U.S. Food and Drug Administration has declined to approve Johnson & Johnson's rheumatoid arthritis drug sirukumab, saying additional clinical data is needed to further evaluate its safety, the company said on Friday. The FDA's decision is in keeping with an advisory panel's recommendation in August that the FDA reject the drug. "We are disappointed by this development as we feel the data accumulated to date support the efficacy and safety of sirukumab," said Dr. Newman Yeilding, head of immunology at J&J's Janssen subsidiary.
They enjoy dominant positions in the healthcare and consumer products industries. But which is the better buy for investors today?